Hello and Welcome to Patientsville.com, Your Source for all ALMOTRIPTAN information. We are dedicated to provide You with ALMOTRIPTAN safety information. Learn about ALMOTRIPTAN serious adverse events reported to Food and Drug Administration (FDA).
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Bookmark to:
Recent Questions
Participate Now!
Patients Wiki
ALMOTRIPTAN Safety Reports
Total ALMOTRIPTAN reports: 3.ALMOTRIPTAN FDA safety alerts: No.
Reported hospitalizations: 2.
Read More Here.
Consumer or non-health professional from FRANCE reported ALMOTRIPTAN problem on May 12, 2006. Female patient, 38 years of age, was diagnosed with migraine and was treated with ALMOTRIPTAN. After drug was administered, patient experienced the following problems/side effects: dysgeusia, fall, grand mal convulsion, hypertonia, pallor, rales, vasospasm. ALMOTRIPTAN dosage: 12.5 MG ONCE PO. Patient was hospitalized. Patient recovered.
ALMOTRIPTAN problem was reported by a Consumer or non-health professional from GERMANY on Aug 26, 2005. Female patient, 65 years of age, was diagnosed with migraine and was treated with ALMOTRIPTAN. After drug was administered, patient experienced the following problems/side effects: retinal detachment. ALMOTRIPTAN dosage: unknown. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from FRANCE reported ALMOTRIPTAN problem on Jan 16, 2006. Female patient, 34 years of age, weighting 132.3 lb, was diagnosed with migraine and was treated with ALMOTRIPTAN. After drug was administered, patient experienced the following problems/side effects: dyspnoea, swollen tongue, trismus. ALMOTRIPTAN dosage: 25 MG PO. During the same period patient was treated with XANAX. Patient recovered.